ERBB2 and breast carcinoma: Interestingly, in a dataset of 590 breast cancer patients, we identified a triple-negative and a HER2+ tumour-carrying in-frame fusions involving the ROS1 kinase domain20 (Supplementary Fig. 2f), suggesting that this rare subset of breast cancer patients could be potentially eligible to targeted tyrosine kinase inhibitor-based therapies.